Allergy Therapeutics plc (HHU)

Overview

Allergy Therapeutics plc is a pioneering commercial biotechnology entity focused on the research, development, and commercialization of innovative treatments for allergies. The company operates with a commitment to enhancing the quality of life for individuals suffering from various allergic conditions, leveraging cutting-edge scientific research to address the unmet needs in this medical domain. Since its inception in 2004, Allergy Therapeutics plc has established a significant presence not only within the United Kingdom but also across Central and Southern Europe, alongside a growing international footprint. The company's headquarters are situated in Worthing, the United Kingdom, serving as a hub for its operations and advancements in the field of allergology.

Products and Services

• Pollinex Quattro: A line of injectable allergen-specific immunotherapies, designed to address pollen-related allergies with a focus on grasses, weeds, and trees, leveraging a short-course treatment methodology for effective allergy mitigation.

• Oralvac: A comprehensive sublingual immunotherapy solution aimed at treating a wide range of pollen-related allergies. This product underscores the company's dedication to providing patient-friendly, non-invasive treatment options.

• Venomil: Specialized injectable immunotherapies targeted at treating venom-induced allergies, providing critical care for individuals with severe reactions to insect stings.

• Venom ATL Polistes Dominula: A specific treatment solution for allergies caused by the stings of the Polistes Dominula wasp, reflecting the company's commitment to addressing niche and potentially life-threatening allergic reactions.

• Acarovac Plus: A distinctive immunotherapy option designed for individuals allergic to house dust mites, offering a path towards long-term relief from this pervasive allergen.

• Pollinex: The fundamental line of injectable allergen-specific immunotherapies developed by Allergy Therapeutics plc, providing a cornerstone treatment for various pollen-related allergies.

• Synbiotics: Products that focus on the role of gut health in allergic diseases, offering a novel approach to allergy management through the modulation of the microbiota.

• VLP Peanut: An advanced vaccine candidate aimed at combating peanut allergies, utilizing virus-like particles (VLPs) to provide a highly targeted immune response, showcasing the company's innovation in addressing food allergies.

In addition to these flagship products, Allergy Therapeutics plc is actively involved in the development of novel vaccine solutions for a range of allergens, including pollen, house dust mites, animal fur, and food allergies, particularly peanuts. This diverse product portfolio exemplifies the company's dynamic approach to allergy treatment, encompassing both traditional and cutting-edge methodologies to cater to the variegated needs of allergy sufferers worldwide.